Our pipeline is focused on developing engineered bone morphogenetic proteins (DA-BMPs), which are important in bone and cartilage healing. Current BMPs require high dosages, causing local and systemic side effects. Darnatein's DA-BMPs are designed for great potency at lower doses. These novel proteins retain the low immunogenicity of natural BMPs, minimizing the risk of immune reactions while maximizing therapeutic benefit.

Darnatein’s lead DA biologics are made to be injected directly into affected tissues to promote regeneration of bone or cartilage, with the goal of restoring functionality and reducing pain.

We are currently advancing two therapeutic candidates: DRT-101, a preclinical asset for osteoarthritis, and DRT-102 a clinical-stage asset for spinal fusion. For DRT-101, an IND submission to the MDFS in Korea is targeted for early 2026, with other regulatory agencies to follow. For DRT-102, applications in bone fusions are already in clinical studies in Korea.